KR20180002677A - 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물 - Google Patents

라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물 Download PDF

Info

Publication number
KR20180002677A
KR20180002677A KR1020177032463A KR20177032463A KR20180002677A KR 20180002677 A KR20180002677 A KR 20180002677A KR 1020177032463 A KR1020177032463 A KR 1020177032463A KR 20177032463 A KR20177032463 A KR 20177032463A KR 20180002677 A KR20180002677 A KR 20180002677A
Authority
KR
South Korea
Prior art keywords
hyperglycemia
fmd
chemotherapy
subject
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177032463A
Other languages
English (en)
Korean (ko)
Inventor
발터 디. 롱고
스테파노 디 비아세
Original Assignee
유니버시티 오브 써던 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 써던 캘리포니아 filed Critical 유니버시티 오브 써던 캘리포니아
Publication of KR20180002677A publication Critical patent/KR20180002677A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020177032463A 2015-04-16 2016-04-18 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물 Ceased KR20180002677A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (1)

Publication Number Publication Date
KR20180002677A true KR20180002677A (ko) 2018-01-08

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032463A Ceased KR20180002677A (ko) 2015-04-16 2016-04-18 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물

Country Status (14)

Country Link
US (2) US20160303056A1 (https=)
EP (2) EP3283073A4 (https=)
JP (2) JP2018511625A (https=)
KR (1) KR20180002677A (https=)
CN (1) CN107613979A (https=)
AU (1) AU2016248443B2 (https=)
BR (1) BR112017022244A2 (https=)
CA (2) CA2982875C (https=)
HK (1) HK1249858A1 (https=)
IL (1) IL255026A0 (https=)
MX (1) MX2017013133A (https=)
RU (1) RU2734774C2 (https=)
WO (1) WO2016168802A2 (https=)
ZA (1) ZA201707710B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
EP4164407A4 (en) * 2020-06-14 2024-08-28 L-Nutra Inc. BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
CN103347521B (zh) * 2010-12-06 2018-05-25 全球癌症治疗有限责任公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Also Published As

Publication number Publication date
RU2734774C2 (ru) 2020-10-23
CN107613979A (zh) 2018-01-19
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
EP3283073A2 (en) 2018-02-21
RU2017136423A3 (https=) 2019-09-04
JP2018511625A (ja) 2018-04-26
ZA201707710B (en) 2019-04-24
EP4299061A2 (en) 2024-01-03
CA2982875C (en) 2021-10-19
JP2021008491A (ja) 2021-01-28
EP4299061A3 (en) 2024-02-28
HK1249858A1 (zh) 2018-11-16
EP3283073A4 (en) 2019-02-13
IL255026A0 (en) 2017-12-31
BR112017022244A2 (pt) 2018-07-10
AU2016248443B2 (en) 2021-03-18
US20210137856A1 (en) 2021-05-13
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07
AU2016248443A1 (en) 2017-11-02
RU2017136423A (ru) 2019-05-16
CA2982875A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
KR20180002677A (ko) 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물
CN105008929B (zh) 预防化学毒性和与年龄相关的疾病的方法和膳食
RU2549954C2 (ru) Способы и диетологические составы для повышения эффективности и снижения побочных эффектов лечения рака
KR102811762B1 (ko) 상승된 콜레스테롤 수준 및/또는 상승된 ldl 수준의 감소용 금식 모방 규정식 조성물
AU2020200726B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
KR20130140715A (ko) 최적화된 영양 조제물, 그것으로부터의 맞춤 식이의 선택 방법 및 그것의 사용 방법
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
US12285453B2 (en) Fasting-mimicking diet promotes cancer-free survival in acute lymphoblastic leukemia models
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
HK40002950A (en) Method for providing reasonable protein diet to subject

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200726

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210225

Patent event code: PE09021S02D

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20210927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210225

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200726

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20210927

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20210426

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20201022